BLAU3 Stock Overview
Blau Farmacêutica S.A., a pharmaceutical company, engages in the manufacture, development, and commercialization of private label drugs in Brazil, Colombia, Uruguay, Chile, and internationally.
Blau Farmacêutica Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||R$25.06|
|52 Week High||R$54.92|
|52 Week Low||R$21.55|
|1 Month Change||5.21%|
|3 Month Change||-13.56%|
|1 Year Change||-48.25%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-39.03%|
Recent News & Updates
Blau Farmacêutica S.A. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
Blau Farmacêutica S.A. ( BVMF:BLAU3 ) shareholders are probably feeling a little disappointed, since its shares fell...
|BLAU3||BR Biotechs||BR Market|
Return vs Industry: BLAU3 underperformed the BR Biotechs industry which returned -27.3% over the past year.
Return vs Market: BLAU3 underperformed the BR Market which returned -29.1% over the past year.
|BLAU3 Average Weekly Movement||5.6%|
|Biotechs Industry Average Movement||10.6%|
|Market Average Movement||5.9%|
|10% most volatile stocks in BR Market||9.2%|
|10% least volatile stocks in BR Market||2.9%|
Stable Share Price: BLAU3 is not significantly more volatile than the rest of BR stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: BLAU3's weekly volatility (6%) has been stable over the past year.
About the Company
Blau Farmacêutica S.A., a pharmaceutical company, engages in the manufacture, development, and commercialization of private label drugs in Brazil, Colombia, Uruguay, Chile, and internationally. It operates through Institutional and Retail segments. The company’s medications cover various therapeutic classes, such as immunology, hematology, oncology, nephrology, specialties, and antibiotics.
Blau Farmacêutica Fundamentals Summary
|BLAU3 fundamental statistics|
Is BLAU3 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLAU3 income statement (TTM)|
|Cost of Revenue||R$697.09m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||1.68|
|Net Profit Margin||22.20%|
How did BLAU3 perform over the long term?See historical performance and comparison
1.8%Current Dividend Yield
Is BLAU3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BLAU3?
Other financial metrics that can be useful for relative valuation.
|What is BLAU3's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does BLAU3's PE Ratio compare to its peers?
|BLAU3 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
OFSA3 Ouro Fino Saúde Animal Participações
002880 Shenzhen Weiguang Biological Products
BLAU3 Blau Farmacêutica
Price-To-Earnings vs Peers: BLAU3 is good value based on its Price-To-Earnings Ratio (15x) compared to the peer average (18.9x).
Price to Earnings Ratio vs Industry
How does BLAU3's PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Earnings vs Industry: BLAU3 is good value based on its Price-To-Earnings Ratio (15x) compared to the Global Biotechs industry average (26.9x)
Price to Earnings Ratio vs Fair Ratio
What is BLAU3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||15x|
|Fair PE Ratio||14.1x|
Price-To-Earnings vs Fair Ratio: BLAU3 is expensive based on its Price-To-Earnings Ratio (15x) compared to the estimated Fair Price-To-Earnings Ratio (14.1x).
Share Price vs Fair Value
What is the Fair Price of BLAU3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BLAU3 (R$25.06) is trading above our estimate of fair value (R$20.67)
Significantly Below Fair Value: BLAU3 is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: BLAU3 is good value based on its PEG Ratio (0.9x)
Discover undervalued companies
How is Blau Farmacêutica forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLAU3's forecast earnings growth (16.6% per year) is above the savings rate (9.2%).
Earnings vs Market: BLAU3's earnings (16.6% per year) are forecast to grow faster than the BR market (6.6% per year).
High Growth Earnings: BLAU3's earnings are forecast to grow, but not significantly.
Revenue vs Market: BLAU3's revenue (16.4% per year) is forecast to grow faster than the BR market (5.6% per year).
High Growth Revenue: BLAU3's revenue (16.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BLAU3's Return on Equity is forecast to be high in 3 years time (22.5%)
Discover growth companies
How has Blau Farmacêutica performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BLAU3 has a high level of non-cash earnings.
Growing Profit Margin: BLAU3's current net profit margins (22.2%) are lower than last year (24%).
Past Earnings Growth Analysis
Earnings Trend: BLAU3's earnings have grown significantly by 31.5% per year over the past 5 years.
Accelerating Growth: BLAU3's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BLAU3 had negative earnings growth (-2.8%) over the past year, making it difficult to compare to the Biotechs industry average (8.2%).
Return on Equity
High ROE: BLAU3's Return on Equity (18%) is considered low.
Discover strong past performing companies
How is Blau Farmacêutica's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: BLAU3's short term assets (R$1.6B) exceed its short term liabilities (R$302.9M).
Long Term Liabilities: BLAU3's short term assets (R$1.6B) exceed its long term liabilities (R$332.7M).
Debt to Equity History and Analysis
Debt Level: BLAU3 has more cash than its total debt.
Reducing Debt: BLAU3's debt to equity ratio has reduced from 123% to 19.2% over the past 5 years.
Debt Coverage: BLAU3's debt is well covered by operating cash flow (43%).
Interest Coverage: BLAU3 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Blau Farmacêutica current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BLAU3's dividend (1.81%) is higher than the bottom 25% of dividend payers in the BR market (1.76%).
High Dividend: BLAU3's dividend (1.81%) is low compared to the top 25% of dividend payers in the BR market (7.89%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether BLAU3's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if BLAU3's dividend payments are increasing as they only just started paying a dividend.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (8.7%), BLAU3's dividend payments are thoroughly covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: BLAU3 is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Mr. Marcelo Rodolfo Hahn is the Founder and serves as Chief Executive Officer at Blau Farmacêutica S/A and serves as its Deputy Chairman of the Board. Mr. Hahn served as President at Blau Farmacêutica S/A.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Blau Farmacêutica S.A.'s employee growth, exchange listings and data sources
- Name: Blau Farmacêutica S.A.
- Ticker: BLAU3
- Exchange: BOVESPA
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: R$4.496b
- Shares outstanding: 179.39m
- Website: https://www.blau.com
Number of Employees
- Blau Farmacêutica S.A.
- Rodovia Raposo Tavares, 2833, km 30,5
- Barro Branco
- São Paulo
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/30 00:00|
|End of Day Share Price||2022/06/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.